Not yet recruitingPhase 2NCT07141186

QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy

Studying Adenocarcinoma of the cervix uteri

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Principal Investigator
Zhiyong Yuan
Tianjin Medical University Cancer Institute and Hospital
Intervention
QL1706 (bispecific antibody targeting PD-1 and CLTA-4)(drug)
Enrollment
50 target
Eligibility
18 years · FEMALE
Timeline
20252030

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07141186 on ClinicalTrials.gov

Other trials for Adenocarcinoma of the cervix uteri

Additional recruiting or active studies for the same condition.

See all trials for Adenocarcinoma of the cervix uteri

← Back to all trials